drugset / Trial / NCT01031992
Tranexamic Acid and Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT)
Phase 3
Completed
23 enrolled
University Hospital, Saarland
Baxter Healthcare Corporation · collabPharmacia GmbH, Erlangen, Germany · collab
RandomizedCrossoverQuadruple-blindTreatment
Summary
Hereditary hemorrhagic telangiectasia (HHT, Rendu-Osler-Weber Syndrome) is associated with frequent nosebleeds in the majority of cases. Several reports in the literature support the use of antifibrinolytics like Tranexamic acid to reduce nosebleeds. The objectives of the study are to test if Tranexamic acid taken orally can 1. improve anemia (lead to an increased hemoglobin level) 2. reduce nosebleeds.
Timeline
- Start
- 2002-03
- Primary completion
- 2002-08
- Completion
- 2002-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Tranexamic Acid | Small molecule | 1 g | Oral |